Last reviewed · How we verify
CD0271 0.3% / CD1579 2.5%
CD0271 and CD1579 are topical agents that work synergistically to reduce inflammation and improve skin barrier function in dermatological conditions.
CD0271 and CD1579 are topical agents that work synergistically to reduce inflammation and improve skin barrier function in dermatological conditions. Used for Inflammatory dermatological condition (specific indication not publicly disclosed).
At a glance
| Generic name | CD0271 0.3% / CD1579 2.5% |
|---|---|
| Sponsor | Galderma R&D |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
This is a fixed-dose combination product in development by Galderma for topical dermatological use. CD0271 and CD1579 are designed to work together to address inflammatory skin conditions, though the specific molecular mechanisms of each component are not publicly detailed. The combination approach suggests complementary anti-inflammatory and/or skin-normalizing effects.
Approved indications
- Inflammatory dermatological condition (specific indication not publicly disclosed)
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CD0271 0.3% / CD1579 2.5% CI brief — competitive landscape report
- CD0271 0.3% / CD1579 2.5% updates RSS · CI watch RSS
- Galderma R&D portfolio CI